The announcement of a distribution agreement for Mpox detection kits in multiple countries is a significant business development for Virax Biolabs. The high sensitivity and specificity of the kits, along with quick result times, enhance their market appeal. This news has led to a substantial increase in the stock price, reflecting positive investor sentiment and potential revenue growth.